Evidence map›Paper›PMID 38821769›Full record

ReviewJournal of autoimmunity2024

Infectious and non-infectious precipitants of sarcoidosis.

Ozioma S Chioma, ZaDarreyal Wiggins, Samantha Rea, Wonder P Drake

Abstract readReview
In one paragraph

Review in Journal of autoimmunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ozioma S ChiomaDivision of Infectious Disease, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
ZaDarreyal WigginsDivision of Infectious Disease, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
Samantha ReaDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Wonder P DrakeDivision of Infectious Disease, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: wdrake@som.umaryland.edu.

Funding

Interdisciplinary Training in Rheumatic DiseasesT32AR059039 · NIAMS · VANDERBILT UNIVERSITY · PI Tracy Minan Frech, AMY S MAJOR · 2010 to 2026
$4.3M
Vanderbilt SCHolars in HIV and Heart, Lung, Blood, and Sleep ReSearch (V-SCHoLARS, K12)K12HL143956 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FREIBERG, MATTHEW S, KOETHE, JOHN · 2018 to 2022
$1.6M
Mentoring in Translational Research in Interstitial Lung DiseasesK24HL127301 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Wonder P. Drake · 2016 to 2026
$1.2M
NHLBI NIH HHS K12 HL143956NHLBI NIH HHS K24 HL127301NIAMS NIH HHS T32 AR059039
6 · The paper itself

Abstract

Sarcoidosis is a chronic inflammatory disease that can affect any organ in the body. Its exact cause remains unknown, but it is believed to result from a combination of genetic and environmental factors. Some potential causes of sarcoidosis include genetics, environmental triggers, immune system dysfunction, the gut microbiome, sex, and race/ethnicity. Genetic mutations are associated with protection against disease progression or an increased susceptibility to more severe disease, while exposure to certain chemicals, bacteria, viruses, or allergens can trigger the formation of immune cell congregations (granulomas) in different organs. Dysfunction of the immune system, including autoimmune reactions, may also contribute. The gut microbiome and factors such as being female or having African American, Scandinavian, Irish, or Puerto Rican heritage are additional contributors to disease outcome. Recent research has suggested that certain drugs, such as anti-Programmed Death-1 (PD-1) and antibiotics such as tuberculosis (TB) drugs, may raise the risk of developing sarcoidosis. Hormone levels, particularly higher levels of estrogen and progesterone in women, have also been linked to an increased likelihood of sarcoidosis. The diagnosis of sarcoidosis involves a comprehensive assessment that includes medical history, physical examination, laboratory tests, and imaging studies. While there is no cure for sarcoidosis, the symptoms can often be effectively managed through various treatment options. Treatment may involve the use of medications, surgical interventions, or lifestyle changes. These disparate factors suggests that sarcoidosis has multiple positive and negative exacerbants on disease severity, some of which can be ameliorated and others which cannot.

Indexed as

SarcoidosisDisease SusceptibilityFemaleGastrointestinal MicrobiomeGenetic Predisposition to DiseaseHumansRisk FactorsCausesDrugsEnvironmentEthnicityGeneticsGut microbiomeHormoneImmune systemRaceSarcoidosisSex

Identifiers

PMID38821769
PMCPMC11607178

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.